A Year of COVID-19: New Wave of Health Concerns among Americans

Obstructive Sleep Apnea and Hypertension Update: FDA Clears Phase 2 Trial of Lorundrostat, an Oral Aldosterone Synthase Inhibitor

News

Article

The prolonged stress on Americans created by the coronavirus disease 2019 (COVID-19) pandemic continues to negatively affect their mental and physical health, according to the American Psychological Association’s (APA) latest Stress in America™ poll. The annual survey was conducted online by The Harris Poll on behalf of the APA between February 19-24, 2021, among 3013 adults aged ≥18 years.

In the slides below, find key survey results including the negative mental health impact among essential workers, increased alcohol intake among US adults, how younger adults have fared in the past year, and more.

Related Content

Patient Care Staff

January 17th 2025

Respiratory Tripledemic 2022-23: An Expert Recap

Mineralys Therapeutics also expects topline data from its phase 2 study of lorundrostat for the treatment of uncontrolled hypertension or resistant hypertension when used as an add-on therapy.

April 6th 2023

Novel Tool Predicts Onset Age of Cognitive Impairment and Alzheimer Dementia

William Schaffner, MD, medical director of the NFID, provides an expert recap of the 2022-2023 respiratory virus season for primary care clinicians.

January 16th 2025

Distress Signals: How to Help a Clinician Colleague in Need

The Florey Dementia Index showed robustness across different cohorts but more testing is needed, researchers reported.

February 14th 2023

Annual Incidence of Dementia in US Will Double by 2060, Reaching 1 Million Cases

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Rebekah Bernard, MD, a family physician and national speaker on physician wellness.

Grace Halsey

January 15th 2025

Minimal Distress Reported with Multi-Cancer Early Detection Testing: New Findings from PATHFINDER Trial

Annual incidence of dementia will double in White adults and triple among Black adults. The updated estimates place the lifetime risk of developing dementia after age 55 at 42%.

January 14th 2025

Obstructive Sleep Apnea and Hypertension Update: FDA Clears Phase 2 Trial of Lorundrostat, an Oral Aldosterone Synthase Inhibitor

A new analysis of patient reported outcomes from the PATHFINDER study indicate the potential clinical benefit of early cancer detection.

Related Content

Patient Care Staff

January 17th 2025

Respiratory Tripledemic 2022-23: An Expert Recap

Mineralys Therapeutics also expects topline data from its phase 2 study of lorundrostat for the treatment of uncontrolled hypertension or resistant hypertension when used as an add-on therapy.

April 6th 2023

Novel Tool Predicts Onset Age of Cognitive Impairment and Alzheimer Dementia

William Schaffner, MD, medical director of the NFID, provides an expert recap of the 2022-2023 respiratory virus season for primary care clinicians.

January 16th 2025

Distress Signals: How to Help a Clinician Colleague in Need

The Florey Dementia Index showed robustness across different cohorts but more testing is needed, researchers reported.

February 14th 2023

Annual Incidence of Dementia in US Will Double by 2060, Reaching 1 Million Cases

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Rebekah Bernard, MD, a family physician and national speaker on physician wellness.

Grace Halsey

January 15th 2025

Minimal Distress Reported with Multi-Cancer Early Detection Testing: New Findings from PATHFINDER Trial

Annual incidence of dementia will double in White adults and triple among Black adults. The updated estimates place the lifetime risk of developing dementia after age 55 at 42%.

January 14th 2025